share_log

Arcutis Biotherapeutics | 10-K: Annual report

SEC announcement ·  Feb 27 07:50
Summary by Moomoo AI
Arcutis Biotherapeutics, a commercial-stage biopharmaceutical company, has reported significant developments in its financial performance and business operations for the year ended December 31, 2023. Financially, the company saw a substantial increase in product revenue, netting $29.2 million, a 692% surge from the previous year, primarily driven by the demand for its FDA-approved ZORYVE cream for plaque psoriasis. Other revenue, primarily from the Huadong Agreement, contributed an additional $30.4 million. Despite these revenues, the company incurred a net loss of $262.1 million, a slight improvement from the $311.5 million loss in 2022. Research and development expenses decreased by 39% to $110.6 million, reflecting the completion of certain clinical trials. Selling, general, and administrative expenses rose by 52% to $185.1 million due to increased commercialization efforts. The company's future plans include...Show More
Arcutis Biotherapeutics, a commercial-stage biopharmaceutical company, has reported significant developments in its financial performance and business operations for the year ended December 31, 2023. Financially, the company saw a substantial increase in product revenue, netting $29.2 million, a 692% surge from the previous year, primarily driven by the demand for its FDA-approved ZORYVE cream for plaque psoriasis. Other revenue, primarily from the Huadong Agreement, contributed an additional $30.4 million. Despite these revenues, the company incurred a net loss of $262.1 million, a slight improvement from the $311.5 million loss in 2022. Research and development expenses decreased by 39% to $110.6 million, reflecting the completion of certain clinical trials. Selling, general, and administrative expenses rose by 52% to $185.1 million due to increased commercialization efforts. The company's future plans include continued commercialization of ZORYVE cream and foam, advancing clinical trials, and pursuing regulatory submissions. Arcutis also plans to focus on developing ARQ-234 and ARQ-255 for dermatological conditions. The company's cash position, including marketable securities, stood at $272.8 million as of December 31, 2023, with an accumulated deficit of $981.9 million. Arcutis relies on third-party manufacturers and has no internal manufacturing capabilities. The company's strategy involves focusing on validated biological targets and leveraging its drug development platform to address unmet medical needs in dermatology.

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Doc 4

Doc 5

Doc 6

Doc 7

Doc 8

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more